TL;DR
- 1.COL5A1 rs12722 CC genotype appears in 76% of uninjured athletes vs 24% of ACL-injured ones. This single variant predicts tendon repair speed more reliably than training load or age.
- 2.MMP3 rs679620 5A allele drives roughly 2x higher enzyme activity than 6A. Faster matrix turnover compresses the repair timeline but raises re-injury risk if you load too early.
- 3.COL1A1, TGFB1, and NOS3 each add a separate layer to the healing picture. Your combination of all five is what determines your actual repair speed.
- 4.BPC-157, GHK-Cu, and TB-500 each target a different repair bottleneck. The right protocol starts with knowing which gene variant is your limiting factor.
- 5.All five variants appear in 23andMe and AncestryDNA raw data. You do not need a specialized test to check your tendon genetics before starting a repair protocol.
Two athletes. Same torn Achilles. Same BPC-157 protocol at the same dose. One is pain-free and back in the gym at week 8. The other is stalled at week 20, wondering what went wrong. The protocol did not fail. The genetics were different from the start.
Tendon repair speed varies far more between individuals than most protocol guides acknowledge. A 2024 cohort study of 110 team-sport athletes published in the Revista Brasileira de Ortopedia found that a single COL5A1 genetic haplotype appeared in 76% of injury-free athletes versus 24% of ACL-injured ones, with an odds ratio of 5.0 for protection. That single variant explains more variance in tendon susceptibility than training load, sport type, or age combined. And it predicts how fast you heal just as directly as it predicts whether you get injured in the first place.
Protective odds from the COL5A1 CC+B1B1 haplotype vs. the highest-risk genotype in a 2024 Revista Brasileira de Ortopedia cohort of 110 team-sport athletes (p=0.001). This is the single largest published effect size for any gene variant in tendon injury risk literature.
This article covers five genetic variants with real published evidence. For each one, we explain what it does to tendon tissue, what the data shows, and which peptide specifically targets that bottleneck. This is not a genetics lecture. It is a protocol map from your DNA to the right compound.
Think of your tendons as rope bridges built from collagen fibers twisted together. Some people's genetics produce thick, uniform fibers with standard spacing. Others produce thinner, less uniform fibers with wider gaps. The bridge holds either way, but thin-fiber bridges take longer to repair after damage and fail more easily under the same load. Peptides are the repair crew. Knowing which type of bridge you have tells you exactly which crew to call first.
Which 5 genes matter most for tendon healing speed?
The research does not point at hundreds of variants. It concentrates around five that each control a separate part of the repair cascade. Get all five right and your protocol does what it says. Miss the key one for your genotype and the timeline stretches far beyond what any dosing guide predicts.
1. COL5A1 rs12722: the fiber architecture gene
COL5A1 encodes the alpha-1 chain of Type V collagen. Type V collagen does not form structural fibers directly. It acts as the scaffolding controller that determines how Type I collagen fibrils nucleate and space themselves during both growth and repair. Without adequate Type V collagen, Type I fibers grow irregularly, produce heterogeneous diameters, and reduce the mechanical load capacity of the finished tendon.
The BstUI RFLP at rs12722 produces two alleles: C and T. The CC genotype associates with normal Type V collagen expression and regular fibril spacing. The TT genotype associates with reduced Type V collagen output and the heterogeneous fibril pattern that makes tendons both more susceptible to injury and slower to rebuild after one. The 2024 Revista Brasileira de Ortopedia cohort (PMC11374406) found the protective haplotype in 76.2% of uninjured athletes versus 23.8% of ACL-injured athletes. A 2022 meta-analysis of 21 studies in the Journal of Orthopaedic Surgery and Research confirmed rs12722, rs71746744, and rs3196378 each independently raise soft-tissue injury susceptibility.
A May 2026 murine study in the International Journal of Molecular Sciences (IJMS 27:4551, PubMed 42196532) added a critical timing dimension: suppressing COL5A1 during early fibrillogenesis (days 3 to 7 post-injury) reduced tendon stiffness and maximum load at failure, while suppression in the later remodeling phase left quasi-static mechanics intact but altered viscoelastic behavior. TT carriers are producing less COL5A1 throughout both windows simultaneously. Their repair deficit is not just structural. It is temporal.
"COL5A1 rs12722, rs71746744, and rs3196378 each independently increase soft-tissue injury susceptibility across a meta-analysis of 21 studies, confirming that Type V collagen architecture is the primary replicated genetic bottleneck in tendon injury risk across sports populations."
Journal of Orthopaedic Surgery and Research, 2022 (JOSR meta-analysis, 21 studies)
The peptide that most directly compensates for COL5A1 insufficiency is BPC-157. The compound upregulates Type I collagen synthesis in tendon fibroblasts and activates the FAK-paxillin pathway that governs early fibrillogenesis, exactly the window where TT genotypes show the most pronounced deficit. A 2025 systematic review in Sports Health (Vasireddi et al., DOI 10.1177/15563316251355551) confirmed BPC-157 consistently upregulates collagen synthesis across animal models with stronger mechanistic evidence than any other repair peptide studied. TT carriers are the genotype with the most to gain from this effect because they are starting from the weakest baseline. See why TT carriers respond differently on the standard protocol in the full BPC-157 tendon non-responder guide.
2. COL1A1 rs1800012: the fiber strength gene
COL1A1 encodes the primary structural chain of Type I collagen, which makes up roughly 65 to 80% of dry tendon weight. The Sp1 polymorphism at rs1800012 sits in the COL1A1 promoter region. Carriers of the T allele produce less Type I collagen per fibroblast activation event. TT homozygotes are rare (under 5% in most populations), which limits statistical power in population studies. Functional data at the cell and tissue level is more consistent: reduced promoter activity means less collagen output per repair cycle.
A 2025 International Journal of Sports Medicine meta-analysis of 1,687 injury cases and 2,227 controls found no statistically significant association at the population level for rs1800012 alone. But the biological mechanism is unambiguous: lower promoter activity means each round of fibroblast activation produces less collagen. In the context of a repair protocol, T allele carriers are rebuilding with less material per stimulus than their genes would otherwise allow.
The peptide most relevant to COL1A1 Sp1 variants is GHK-Cu. Published reviews on GHK-Cu tissue effects document consistent upregulation of COL1A1 mRNA in fibroblast cultures and in vivo models. GHK-Cu appears to activate COL1A1 expression through the promoter in a way that is independent of the specific Sp1 binding site that the T allele disrupts, meaning T allele carriers can still benefit from the external upregulation signal even where the genetic promoter is underactive. For context on what GHK-Cu does across multiple tissue types, see the GHK-Cu before and after guide.
3. MMP3 rs679620: the matrix remodeling speed gene
MMP3 (matrix metalloproteinase-3) breaks down old collagen and proteoglycans to make room for new tissue. The 5A/6A promoter polymorphism at rs679620 changes MMP3 transcriptional activity by roughly 2x. The 5A allele drives higher promoter activity, meaning faster ECM breakdown and faster matrix turnover. The 6A allele produces lower activity and slower turnover.
Neither allele is simply better. Fast turnover (5A/5A) clears old tissue faster, which accelerates the early phase of tendon repair. But faster breakdown means the temporary scaffold degrades before new collagen can organize properly, increasing re-injury risk during the remodeling phase. Slow turnover (6A/6A) provides more structural stability but can leave inflammatory debris in the healing zone longer than ideal.
A 2025 prospective cohort study (PMC12610566, n=107 with lateral elbow tendinopathy, 104-week follow-up with platelet-rich plasma) found that high-MMP3-activity genotypes achieved the minimum clinically important difference more often (p=0.007 after correction) with a mean effect size of d=0.67 at 104 weeks. PRP and peptides are different interventions, but both work through collagen synthesis and matrix remodeling. The MMP3 genotype appears to predict treatment response across multiple repair-stimulus approaches.
The practical implication: 5A/5A users should plan a robust maintenance phase to prevent the turnover advantage from becoming a structural deficit post-cycle. 6A/6A users should expect a slower ramp-up but a more stable remodeling phase overall. For how the TB-500 maintenance phase addresses this specifically, see the TB-500 dosage and protocol guide.
4. TGFB1 codon 10: the scar quality gene
Transforming growth factor beta-1 is the primary signal that drives fibroblast activation, collagen deposition, and scar tissue formation during healing. The codon 10 polymorphism produces either Leucine (Leu) or Proline (Pro) at position 10 of the signal peptide, shifting TGF-beta-1 secretion efficiency. Pro/Pro homozygotes have higher TGF-beta-1 signaling activity and a more fibrosis-prone healing response. They form more scar tissue, faster, which closes the injury gap but reduces the final mechanical quality of the repaired tendon. Leu/Leu carriers have lower signaling activity and may heal more slowly but with better collagen fiber organization.
Excess TGF-beta-1 is a primary driver of the fibrotic remodeling that reduces tendon strength after injury. Tendons that heal with high scar tissue content are weaker than native tissue and re-injure more easily under the same load. The most studied peptide for anti-fibrotic tendon effects is TB-500 (thymosin beta-4). The 2026 Applied Sciences scoping review (MDPI, 16:6202) confirmed thymosin beta-4 consistently reduces fibrotic marker deposition and promotes organized collagen fiber alignment in preclinical models. For Pro/Pro TGF-beta-1 carriers, TB-500 anti-fibrotic action is not a minor secondary benefit. It is the primary reason to include it in the protocol.
5. NOS3 Glu298Asp (rs1799983): the blood vessel rebuilding gene
Tendons are largely avascular. The core of most tendons has limited direct blood supply. After injury, vascular regrowth into the healing zone is critical for delivering oxygen, growth factors, and repair cells. NOS3 encodes endothelial nitric oxide synthase (eNOS), the primary enzyme driving blood vessel formation and vasodilation in healing tissue.
The Glu298Asp variant at rs1799983 reduces eNOS activity in T allele carriers. Lower eNOS means slower vascular regrowth into the injury zone, which extends the timeline for every downstream repair event that depends on adequate oxygen and growth factor delivery. T allele carriers are not failing at collagen synthesis or matrix remodeling in isolation. They are slowing the delivery of the raw materials those processes need.
Both BPC-157 and TB-500 target this pathway. BPC-157 activates eNOS and VEGFR2 simultaneously, promoting nitric oxide production and new vessel growth. TB-500 drives angiogenesis through a separate thymosin pathway. T allele carriers at NOS3 get the most from either peptide because they start from the lowest vascular regrowth baseline. Stacking both is justified for T allele homozygotes because the two angiogenic mechanisms are additive, not redundant. The comparison of how these two peptides handle muscle and connective tissue injury is covered in depth in the BPC-157 vs TB-500 head-to-head review.
Why two people on the same BPC-157 protocol see 8-week vs 20-week healing timelines
The five variants above affect completely different stages of tendon repair. A person with COL5A1 TT, MMP3 6A/6A, and NOS3 T allele together has three separate bottlenecks: weak fiber architecture, slow matrix turnover, and poor vascular regrowth. BPC-157 alone addresses the collagen synthesis and NOS3 components. It does not directly address MMP3 turnover speed or TGF-beta-1 fibrosis. Running BPC-157 without addressing those other bottlenecks leaves part of the problem untreated.
An 8-week responder likely carries: COL5A1 CC (good fiber architecture baseline), MMP3 5A/5A (fast matrix turnover), and normal NOS3 (adequate vascular regrowth). Every stage of repair proceeds quickly. BPC-157 accelerates an already-capable system.
A 20-week responder likely carries: COL5A1 TT (poor baseline fiber architecture), MMP3 6A/6A (slow matrix turnover), and NOS3 T allele (slower vascular regrowth). Every stage runs at reduced capacity. BPC-157 compensates for two of these. The third stage runs late regardless.
| Variant | Risk genotype | Effect on healing | Primary peptide |
|---|---|---|---|
| COL5A1 rs12722 | TT | Weak fiber architecture, slow early remodeling | BPC-157 (FAK-paxillin, collagen synthesis) |
| COL1A1 rs1800012 | T allele | Lower Type I collagen output per repair cycle | GHK-Cu (COL1A1 promoter upregulation) |
| MMP3 rs679620 | 6A/6A | Slow matrix remodeling; debris lingers longer | TB-500 (progenitor cell migration) |
| TGFB1 codon 10 | Pro/Pro | Excess fibrosis, weaker final tendon strength | TB-500 (anti-fibrotic collagen organization) |
| NOS3 rs1799983 | T allele | Slower vascular regrowth into healing zone | BPC-157 + TB-500 (additive eNOS effect) |
The proportion of uninjured team-sport athletes carrying the protective COL5A1 haplotype in the 2024 Revista Brasileira de Ortopedia cohort, versus 24% of athletes who had suffered ACL tears. The same architecture advantage that protects against injury also shortens the recovery timeline after one.
How do you pick the right peptide based on which genes you carry?
COL5A1 TT is your primary bottleneck
BPC-157 is first. Its FAK-paxillin pathway activation and Type I collagen synthesis upregulation directly compensate for the fiber architecture deficit this genotype creates. Start with a 6-week loading protocol at 250 to 500 mcg subcutaneously, injected near the injury site. Expect a slower ramp-up than standard responders, with the primary response window at weeks 5 to 8 rather than 3 to 5. Extending the protocol to 8 weeks is justified for TT carriers specifically because the early fibrillogenesis window runs longer in this genotype.
NOS3 T allele plus COL5A1 TT is your combination
Stack BPC-157 and TB-500 from the start. The mechanisms are additive: BPC-157 handles fiber synthesis and eNOS activation locally at the injury site, TB-500 handles systemic vascular regrowth and anti-fibrotic remodeling. Inject BPC-157 locally (near the injury) and TB-500 in the abdomen. Their mechanisms work on different parts of the repair cascade simultaneously with no receptor competition between them.
COL1A1 Sp1 T allele is your primary finding
GHK-Cu is the first addition alongside BPC-157. It activates COL1A1 expression through a pathway that bypasses the Sp1 binding site the T allele disrupts, giving you Type I collagen upregulation through a channel that the genetic bottleneck cannot block. Add GHK-Cu at 2 mg subcutaneously 3 to 5 times per week for the first 6 weeks alongside your primary repair peptide.
How to check your connective tissue genes in 23andMe or AncestryDNA data
All five variants above appear on standard consumer DNA arrays. You do not need a specialized clinical test. If you have 23andMe, AncestryDNA, or MyHeritage raw data, look up these rsIDs directly in your download file.
The relevant identifiers: rs12722 (COL5A1), rs1800012 (COL1A1 Sp1), rs679620 (MMP3), rs1800469 (TGFB1 codon 10), rs1799983 (NOS3 Glu298Asp). Search for each. Your genotype will appear as a two-letter code. Naming conventions in raw data sometimes differ from the published allele names due to strand orientation. If a genotype does not immediately match the published risk allele, the 23andMe peptide guide explains how to interpret raw strand data and which providers cover each of these variants.
Your PeptidesDNA report pulls COL5A1, NOS3, MMP3, and COL1A1 into a single connective tissue score alongside the full peptide match panel. See how your specific variant combination ranks against the BPC-157 genetic match profile before committing to an 8 to 12 week protocol.
Verdict: The difference between an 8-week tendon recovery and a 20-week one is usually not the peptide. It is the genetic bottleneck you did not know you had. COL5A1 is the most replicated genetic predictor of tendon injury risk in the published literature, with an odds ratio of 5.0 between the highest-risk and lowest-risk haplotypes. MMP3, COL1A1, TGFB1, and NOS3 add four more layers that collectively explain most of the individual variation in repair speed that protocol guides treat as unexplained noise. BPC-157, GHK-Cu, and TB-500 each address a different bottleneck in this chain. The right protocol starts with knowing which bottleneck is yours. Upload your genetic data or order a DNA kit to get your connective tissue variant profile alongside the full peptide match report.
Your DNA shapes how you respond to every peptide in this report.
A personalized report scores 25+ peptides against your unique genetic profile — including the ones covered in this article.
Frequently asked questions
What is COL5A1 and how does it affect tendon healing?
COL5A1 encodes the alpha-1 chain of Type V collagen, which controls how Type I collagen fibrils nucleate and space themselves during tendon formation and repair. Carriers of the TT genotype at rs12722 produce less functional Type V collagen, resulting in irregularly spaced fibers with more variable diameters. This makes tendons more susceptible to injury and slower to rebuild structurally sound tissue after one occurs. A 2024 cohort study (Revista Brasileira de Ortopedia, PMC11374406) found the protective COL5A1 haplotype in 76% of uninjured athletes versus 24% of ACL-injured athletes, with an odds ratio of 5.0 for protection.
Why is BPC-157 not working on my tendon?
BPC-157 works primarily by upregulating Type I collagen synthesis and activating the FAK-paxillin pathway that governs early fibrillogenesis. If your main bottleneck is MMP3-driven slow matrix remodeling or TGF-beta-1-driven excess fibrosis, BPC-157 does not directly address either. COL5A1 TT carriers often experience longer response windows (weeks 5 to 8 rather than 3 to 5) because the fiber architecture deficit runs longer than the standard protocol assumes. Non-response almost always reflects a mismatch between a compound's mechanism and the specific repair bottleneck, not product quality.
What does MMP3 5A/6A mean for tendon repair speed?
MMP3 is the enzyme that breaks down old extracellular matrix to make room for new collagen during tissue remodeling. The 5A allele produces roughly 2x higher MMP3 promoter activity than 6A in vitro. 5A carriers remodel faster, compressing the repair timeline but raising re-injury risk if load is applied before the new collagen has organized. 6A carriers remodel more slowly with a more stable scaffold during the organization phase. A 2025 104-week PRP follow-up study (PMC12610566) found the high-MMP3-activity genotype achieved better long-term outcomes with an effect size of d=0.67 at 104 weeks.
Does GHK-Cu help tendon repair?
GHK-Cu consistently upregulates COL1A1 mRNA expression in fibroblast cultures and in preclinical models, which makes it directly relevant for tendon repair in carriers of the COL1A1 Sp1 T allele. GHK-Cu activates COL1A1 through a promoter pathway that bypasses the Sp1 binding site the T allele disrupts, meaning T allele carriers can benefit from the upregulation signal even where the genetic promoter is underactive. No completed human trial has specifically tested GHK-Cu for tendon repair. The peptide's tendon relevance is mechanistic and supported by preclinical data.
How do I know if I have the COL5A1 TT genotype?
COL5A1 rs12722 appears on 23andMe, AncestryDNA, and most consumer DNA panel raw data. Search for rs12722 in your raw data download file. The genotype will appear as a two-letter code (AA, GA, or GG depending on the strand orientation your array uses, which may differ from the published C and T allele names). Your PeptidesDNA report converts the raw allele code into the clinically relevant interpretation alongside your full connective tissue variant profile.
Should I stack BPC-157 and TB-500 for tendon repair?
The BPC-157 and TB-500 combination is most justified for NOS3 T allele carriers and COL5A1 TT carriers together. BPC-157 handles fiber synthesis and eNOS activation locally at the injury site. TB-500 handles systemic progenitor cell migration, anti-fibrotic remodeling, and vascular regrowth through a separate thymosin pathway. The mechanisms are additive rather than redundant. For average responders without the high-risk combination, BPC-157 alone is typically sufficient. Adding TB-500 is most justified when the NOS3 vascular bottleneck and the COL5A1 fiber architecture deficit are both present.
How long should a tendon repair peptide protocol run for COL5A1 TT carriers?
COL5A1 TT carriers should plan for a minimum 8-week protocol rather than the standard 6 weeks. The 2026 IJMS murine study (PubMed 42196532) confirmed that Type V collagen suppression during early repair (days 3 to 7 post-injury) causes measurable deficits in stiffness and max load, while suppression in the later remodeling phase produces a different, more recoverable pattern. The loading phase must run long enough to cover the full early fibrillogenesis window, which takes longer in TT carriers. Plan for weeks 5 to 8 as the primary response window rather than weeks 3 to 5.
This article is for informational and educational purposes only. It is not medical advice and does not diagnose, treat, cure, or prevent any disease. Consult a qualified healthcare professional before starting any peptide protocol. Individual results vary.